Virtu Financial’s Stoke Therapeutics STOK Stock Holding History

Virtu Financial’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,042	Closed	-$360K	–	2213
2026 Q1	$360K	Buy	+11,042	New	+$362K	0.01%	722

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Virtu Financial's STOK Position: Q2 2026 in Review

Virtu Financial sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 11,042 shares — an estimated $360K sold.

Virtu Financial first reported a position in STOK in Q1 2026 and held it in 1 quarter. The position peaked at $360K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Virtu Financial reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 11,042 Stoke Therapeutics shares in Q2 2026, an estimated $360K.
Virtu Financial first reported a position in Stoke Therapeutics in Q1 2026 and held it in 1 quarter.
Virtu Financial's Stoke Therapeutics position peaked at $360K in Q1 2026.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.